BioCentury | Sep 15, 2020
Finance

Sept. 14 Quick Takes: $70M+ rounds for Escient, Escape, plus Alzheimer’s data lifts Cassava shares and more

...second program, which targets MRGPRX2, into human testing.Escape Bio closes $73M crossover roundNeurodegenerative disease company Escape Bio Inc....
BioCentury | Mar 21, 2020
Management Tracks

Kutok joins Epizyme as CSO; plus ADC Therapeutics, Emulate, E-Scape, MiMedx and RubrYc

...to predict clinical toxicities (see "Chipping Away at Unreliable Animal Data" ). Neurodegenerative diseases company E-Scape Bio...
...VP of discovery biology at IGM Biosciences Inc. (NASDAQ:IGMS). Robin Sawka, BioCentury Staff Epizyme Inc. ADC Therapeutics S.A. Emulate Inc. E-Scape Bio...
BioCentury | Dec 21, 2019
Company News

Management Tracks: Ionis promotes co-founder to CSO; Syros adds Celgene vet Alles to board; plus Encoded, Cygnal, Harvard Medical School, Immunitas and more

...NK cell therapies to treat solid tumors (see "Zelluna’s Solid TCR Plans" ). Neurodegeneration company E-Scape Bio...
...board and is an advising partner at Advantary, which outsources C-suite services. BioCentury Staff Xencor Institut Gustave-Roussy Zelluna Immunotherapy A/S E-Scape Bio...
BioCentury | Aug 23, 2018
Company News

Management tracks: E-Scape, Immunomedics

...Neurodegeneration company E-Scape Bio Inc. (South San Francisco, Calif.) hired Julie Smith as president and CEO. Smith...
...will become SVP of health systems. She was SVP of medical affairs for the Americas. BC Staff E-Scape Bio...
BioCentury | Sep 16, 2017
Finance

Local leverage

...think about China at some point, and we’ll be there to help them.” CNS play E-Scape Bio...
...Hangzhou, China CanSino Biologics Inc., Tianjin, China China Food and Drug Administration (CFDA), Beijing, China E-Scape Bio...
BioCentury | Sep 14, 2017
Strategy

Numerate’s Intelligence

...spun out a partnered project on small molecule ApoE4 modulators for Alzheimer’s disease to form E-Scape Bio...
...fatty acids -- to treat neurodegenerative diseases such as Alzheimer’s disease. Companies and Institutions Mentioned E-Scape Bio...
BioCentury | Jul 21, 2017
Emerging Company Profile

Targeting APOE4

...a Parkinson's candidate to the clinic. Development timelines for both programs are undisclosed. COMPANY PROFILE E-Scape Bio...
...Ventures, Sutter Hill Ventures Interim CEO: Leon Chen Patents: Not disclosed Companies and Institutions Mentioned E-Scape Bio...
...McCallister, E. "Not dead yet." BioCentury (2016) Osherovich, L. "Alzheimer's rewind." BioCentury (2011) Virginia Li, Staff Writer E-Scape Bio...
BioCentury | Jul 15, 2017
Finance

E-scape's expansion

...The opportunity to take up a second asset that will expand E-Scape Bio Inc. 's pipeline and...
...declined to disclose the trigger or timing for the remaining $17 million tranche. Virginia Li, Staff Writer E-Scape Bio Apolipoprotein...
BioCentury | Jul 13, 2017
Financial News

E-Scape emerges with $63M series A

...On July 12, neurodegeneration play E-Scape Bio Inc. (South San Francisco, Calif.) emerged from stealth mode with...
...partner at OrbiMed. E-Scape Bio Inc. , South San Francisco, Calif. Jaime De Leon Johnson & Johnson Novo Holdings A/S E-Scape Bio...
BioCentury | Jul 12, 2017
Financial News

E-Scape emerges with $63M series A

...Neurodegeneration play E-Scape Bio Inc. emerged from stealth mode with a tranched $63 million series A round...
...of patients with Parkinson's disease. Chen declined to disclose details. Virginia Li Apolipoprotein E (APOE) epsilon 4 (APOE4) E-Scape Bio...
Items per page:
1 - 10 of 11
BioCentury | Sep 15, 2020
Finance

Sept. 14 Quick Takes: $70M+ rounds for Escient, Escape, plus Alzheimer’s data lifts Cassava shares and more

...second program, which targets MRGPRX2, into human testing.Escape Bio closes $73M crossover roundNeurodegenerative disease company Escape Bio Inc....
BioCentury | Mar 21, 2020
Management Tracks

Kutok joins Epizyme as CSO; plus ADC Therapeutics, Emulate, E-Scape, MiMedx and RubrYc

...to predict clinical toxicities (see "Chipping Away at Unreliable Animal Data" ). Neurodegenerative diseases company E-Scape Bio...
...VP of discovery biology at IGM Biosciences Inc. (NASDAQ:IGMS). Robin Sawka, BioCentury Staff Epizyme Inc. ADC Therapeutics S.A. Emulate Inc. E-Scape Bio...
BioCentury | Dec 21, 2019
Company News

Management Tracks: Ionis promotes co-founder to CSO; Syros adds Celgene vet Alles to board; plus Encoded, Cygnal, Harvard Medical School, Immunitas and more

...NK cell therapies to treat solid tumors (see "Zelluna’s Solid TCR Plans" ). Neurodegeneration company E-Scape Bio...
...board and is an advising partner at Advantary, which outsources C-suite services. BioCentury Staff Xencor Institut Gustave-Roussy Zelluna Immunotherapy A/S E-Scape Bio...
BioCentury | Aug 23, 2018
Company News

Management tracks: E-Scape, Immunomedics

...Neurodegeneration company E-Scape Bio Inc. (South San Francisco, Calif.) hired Julie Smith as president and CEO. Smith...
...will become SVP of health systems. She was SVP of medical affairs for the Americas. BC Staff E-Scape Bio...
BioCentury | Sep 16, 2017
Finance

Local leverage

...think about China at some point, and we’ll be there to help them.” CNS play E-Scape Bio...
...Hangzhou, China CanSino Biologics Inc., Tianjin, China China Food and Drug Administration (CFDA), Beijing, China E-Scape Bio...
BioCentury | Sep 14, 2017
Strategy

Numerate’s Intelligence

...spun out a partnered project on small molecule ApoE4 modulators for Alzheimer’s disease to form E-Scape Bio...
...fatty acids -- to treat neurodegenerative diseases such as Alzheimer’s disease. Companies and Institutions Mentioned E-Scape Bio...
BioCentury | Jul 21, 2017
Emerging Company Profile

Targeting APOE4

...a Parkinson's candidate to the clinic. Development timelines for both programs are undisclosed. COMPANY PROFILE E-Scape Bio...
...Ventures, Sutter Hill Ventures Interim CEO: Leon Chen Patents: Not disclosed Companies and Institutions Mentioned E-Scape Bio...
...McCallister, E. "Not dead yet." BioCentury (2016) Osherovich, L. "Alzheimer's rewind." BioCentury (2011) Virginia Li, Staff Writer E-Scape Bio...
BioCentury | Jul 15, 2017
Finance

E-scape's expansion

...The opportunity to take up a second asset that will expand E-Scape Bio Inc. 's pipeline and...
...declined to disclose the trigger or timing for the remaining $17 million tranche. Virginia Li, Staff Writer E-Scape Bio Apolipoprotein...
BioCentury | Jul 13, 2017
Financial News

E-Scape emerges with $63M series A

...On July 12, neurodegeneration play E-Scape Bio Inc. (South San Francisco, Calif.) emerged from stealth mode with...
...partner at OrbiMed. E-Scape Bio Inc. , South San Francisco, Calif. Jaime De Leon Johnson & Johnson Novo Holdings A/S E-Scape Bio...
BioCentury | Jul 12, 2017
Financial News

E-Scape emerges with $63M series A

...Neurodegeneration play E-Scape Bio Inc. emerged from stealth mode with a tranched $63 million series A round...
...of patients with Parkinson's disease. Chen declined to disclose details. Virginia Li Apolipoprotein E (APOE) epsilon 4 (APOE4) E-Scape Bio...
Items per page:
1 - 10 of 11